Venus Medtech (Hangzhou) is a corporate investor based in Hangzhou, China, founded in 2009. Verified contact details, AUM data, and investment preferences on FindLPs.
Hangzhou Qiming Medical Devices Co., Ltd. is China's leading transcatheter heart valve medical device company. The company's independently developed product VenusA-Valve is the first transcatheter aortic valve replacement ("TAVR") product approved by the National Drug Administration ("NMPA") and commercially available in China. As a pioneer in China's transcatheter heart valve industry, the company has a first-mover advantage. The company’s mission is to become a global leader in the development and commercialization of transcatheter solutions for structural heart disease.
Investment types: Early Stage, Early Stage: Seed, Early Stage: Start-up, Expansion / Late Stage, Venture (General)
Sectors & themes: Healthcare, Information Technology, Semiconductors
Preferred geographies: Asia, BRIC, Emerging Markets, Greater China
Location: 3/F, Building 2, 88 Jiangling Road Binjiang District
FindLPs holds verified direct email addresses and phone numbers for decision-makers at Venus Medtech (Hangzhou). Contact details are masked on the free plan — start a plan to unlock full access and CSV export.
Unlock Contact DetailsSearch 25,850 limited partners with verified contact details.
LP firm data compiled from public regulatory filings (SEC Form ADV, FCA, AIFMD disclosures), company websites and press releases, LinkedIn public profiles, and verified outbound email testing. AUM figures reflect self-reported values from filings and may lag by 1–2 fiscal quarters; bands are normalized in USD. We do not publish personal residential information; firms or individuals may request removal at /contact. Methodology & sources · Updated July 2026.